Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 4 2Phase 1 2Phase 1/2 1

Status

Recruiting 2Unknown 1Not yet recruiting 1

Sponsor Class

OTHER 4INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 3Sarcoma 1

Conditions

Lymphoma, B-Cell 3Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Dendritic Cell Sarcoma, Interdigitating 1

Interventions

Cisplatin 1041Cyclophosphamide 973Carboplatin 954Radiotherapy 893Bevacizumab 847Gemcitabine 817pembrolizumab 759Paclitaxel 738Docetaxel 734Oxaliplatin 706Capecitabine 649Fluorouracil 564Rituximab 559Nivolumab 506Dexamethasone 487Etoposide 468Doxorubicin 458Irinotecan 442Drug Therapy 402Leucovorin 377Cytarabine 342Cetuximab 340Lenalidomide 326Trastuzumab 323Pemetrexed 315durvalumab 295Filgrastim 287Magnetic Resonance Spectroscopy 278Temozolomide 275Prednisone 274

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × OTHER × relmacabtagene autoleucel × Clear all
NCT07077512 2026-01-21

Relmacabtagene Autoleucel Combined With Sintilimab for Relapsed/Refractory B-cell Lymphoma

Sun Yat-sen University

Phase 2 Recruiting
30 enrolled
Lymphoid

Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT07326371 2026-01-08

Glofitamab Combined With CAR-T Therapy in R/R DLBCL

Ruijin Hospital

Phase 2 Not yet recruiting
24 enrolled
Sarcoma

Dendritic Cell Sarcoma, Interdigitating

NCT06365671 2026-01-06

CAR-T Following ASCT for Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (R/R B-NHL) With High-Risk Prognostic Factors

Ruijin Hospital

Phase 2 Recruiting
16 enrolled
Lymphoid

Lymphoma, B-Cell

NCT05590221 2024-01-08

Relmacabtagene Autoleucel as First-Line Therapy for High-Risk Large B-Cell Lymphoma

Peking University Cancer Hospital & Institute

Phase 2 Unknown
20 enrolled
Lymphoid

Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡